Severe Aplastic Anemia

Proposal

The management of severe aplastic anemia (AA) evolved rapidly for these 2 decades. The advances in the treatment of AA have largely been the result of analyses of large registration data and prospective collaborative studies. Especially, SAA working group in European Group for Blood and Marrow Transplantation (EBMT) has contributed to much of progress in this field. In Europe and the United State, aplastic anemia is a rare disease, with annual incidence ranging from 1.0 to 2.0 per million per year. However, in Asia, AA is much more common. In several countries, AA is the most frequent indication for hematopoietic stem cell transplantation.

Immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine has been an alternative treatment for patients who do not have suitable donors. Until now, horse ATG has been commonly used for the treatment of AA in Asia and Europe. However, the production of horse ATG has been discontinued and replaced by rabbit ATG. Because there is no large study to evaluate the effectiveness of rabbit ATG for treatment of AA, it is urgently necessary to conduct a dose finding study for rabbit ATG. To obtain the result, a large number of patients are required. Because this is a common issue in Asia and Europe, the SAA working group in EBMT proposes collaboration with APBMT group.

Based on these backgrounds, I propose to organize a working group for severe aplastic anemia in APBMT group.

Prof. Seiji Kojima MD, PhD
 The First Chairman of the Severe Aplastic Anemia Working Group

Meetings

Minutes of Severe Aplastic Anemia Working Group Meetings are available here Click on the following links to download.
Note: Access to the document links within the Minutes pages is restricted to members only and requires a password.

Minutes of the Aplastic Anemia Working Group – Aug 2009

Minutes of the Aplastic Anemia Working Group – Feb 2010

Minutes of the Aplastic Anemia Working Group – Oct 2010

 

Members

Chairman: Hoon Kook (Korea)

kojimas@med.nagoya-u.ac.jp

WG Members

Name Country Institute
Yoshihisa Kodera Japan Aichi Medical University
Asahito Hama Japan Nagoya University
Dae Chul Jeong Korea Catholic University of Korea
Kook Hoon Korea Chonnam National University
Zhang Feng Kui China Institute of Hematology & Blood Disease Hospital
Wang Yue China Jilin University
Honorata G Baylon Philippines Luke's Medical Center, Blood and Marrow Transplant Center
Tai-ju Hwang Korea Chonnam National University,
Jong Wook Lee Korea Catholic University of Korea
Minako Iida Japan Aichi Medical University
Hideki Muramatsu Japan Nagoya University
Tahir Sultan Shamsi Pakistan National Institute of Blood Disease & Bone Marrow Transplantation
Shinji Nakao Japan Kanazawa University
Surapol I ssaragrisil Thailand Mahidol University
Michelle POON Singapore National University Hospital
Xiaofan Zhu China Institute of Hematology & Blood Disease Hospital
Tasneem Farzana Pakistan National Institute of Blood Disease & Bone Marrow Transplantation
Akira Shimada Japan Nagoya University
Tnag Jing-Yan China Shanghai Children's medical Center
Teeraya Pualvilai Thailand Mahidol University
Yoshiyuki Takahashi Japan Nagoya University
Shinichiro Okamoto Japan Keio University
Guangsheng HE China Jiangsu Institute of Hematology, Clinical Dept. of Hematology of First Affiliated Hospital of Soochow University
Lily WONG Lee Lee Malaysia Head of Dept. of Hematology, Queen Elizabeth Hospital
Pimjai Niparuck Thailand Mahidol University
Mickey Koh Singapore Deputy Director, Center of Transfusion Medicine Health Sciences Authority, Head-Bone Marrow Transplantation St George's Hospital and Medical School